<DOC>
	<DOCNO>NCT00382694</DOCNO>
	<brief_summary>Multiple myeloma incurable malignant disease evnetuelly relapse primary treatment . Clonal B-cells identify theory cell might sleep primary treatment responsible later relapse . Fluarabine document effect rest divide cell include B-cells . The protocol aim evaluate safety toxicity add fludarabine induction chemotherapy cyclophosphamide dexamethasone high-dose melphalan autologous stem cell support .</brief_summary>
	<brief_title>Fludarabine Added Induction Treatment Untreated Multiple Myeloma Patients</brief_title>
	<detailed_description>This randomise , placebo control , phase II study evaluate toxicity safety fludarabine add CyDex ( cyclophosphamide+dexamethasone ) induction therapy young patient untreated treatment demand multiple myeloma . The treatment regimen Patients randomise diagnosis either CyDex + Placebo ( control Arm A ) CyDex + Fludarabine ( Experimental Arm B ) . OBJECTIVES : - Primary : To determine toxicity safety fludarabine add induction therapy registration side effect adverse event accordance common toxicity criterion ( CTC ) . - Secondary : To quantitate clonal cell bone marrow blood flow cytometry ( MRD ) study new potential prognostic marker identify cytomic , genomic proteomic analysis . - Tertiary : To estimate efficacy fludarabine add induction chemotherapy ( CyDex ) patient multiple myeloma clinical end point : disease response progression free survival .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Multiple myeloma , stage IIII , previously untreated , eligible induction therapy follow high dose treatment support autologous stem cell transplantation . Severe uncontrolled clinical microbiological evidence infection time enrolment . Other active malignancy . Severe coincident heart lung disease include uncontrolled hypertension , unstable angina , congestive heart failure , coronary angioplasty within six month , myocardial infarction within last six month , uncontrolled cardiac arrhythmia . Other severe illness include poorly control diabetes . Haemolytic anaemia ( Coombs positive without evidence haemolysis accept ) . Idiopathic thrombocytopenic purpura . Terminal illness . Allogenic transplantation plan within 6 month . Chemotherapy inclusion . Pregnancy breastfeeding , inadequate contraceptive precaution . Psychiatric disease , abuse alcohol narcotic , disorder might compromise patient ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Induction therapy</keyword>
	<keyword>High-dose melphalan</keyword>
	<keyword>Autologous stem cell support</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Safety</keyword>
	<keyword>Toxicity</keyword>
</DOC>